NCT06720246Recruiting
Impact of Bariatric Surgery and Liraglutide on Cognitive-Behavioral Markers of Long-Term Weight Loss in Obesity
Effects of Bariatric Surgery and Pharmacological Therapy with Liraglutide on Motivational and Inhibitory Processes: Cognitive-Behavioral Markers of Long-Term Weight Loss. a Study on Patients with Obesity.
Source: ClinicalTrials.gov · Last updated 11 Dec 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The present research project aims to study the effects of bariatric surgery and liraglutide administration (in patients already selected for one of these procedures) on two cognitive-behavioral processes partially supported by distinct brain networks: automatic approach tendencies (underpinned by the cue-reactivity network) and behavioral inhibition (underpinned by the cue-regulation network). Additionally, the investigators aim to study how these processes may be modulated by satiety. The secondary objective of the project includes identifying cognitive-behavioral markers that can predict the response to these treatments.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 2 Dec 2024
- Start date
- 26 Jun 2024
- Primary completion date
- 1 May 2027
- Lead sponsor
- I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
- Diseases
- Obesity
- NCT number
- NCT06720246
What you commit to
- Study type: Observational
- Planned participants: 50
- From 26 Jun 2024 to the primary completion date, 1 May 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous diagnosis of significant neurological conditions (e.g., brain injury or dementia) or major psychiatric disorders.
- Current or past psychopharmacological therapy, if prolonged.
Other illness
- Severe medical conditions, including but not limited to: hypertension, significant cardiac disease, or other disorders that may compromise patient safety.
Other
- BMI lower than 30 kg/m².
- Lack of signed informed consent.
- Confirmed pregnancy through self-report and/or breastfeeding.
Who the study is looking for
- Subjects of any ethnicity, aged between 20 and 60 years.
- BMI equal to or greater than 30 kg/m².
- No history of neurological or psychiatric disorders, as confirmed through medical history and neuropsychological screening.
- Signed informed consent and willingness to comply with all study procedures.
- Patients scheduled for surgery, treatment with liraglutide, or a dietary regimen.
Age in the registry: 20 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| IRCCS Ospedale Galeazzi Sant'Ambrogio Coordinator of this site? Confirm its status | Milan | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.